Simpson Thacher represented the underwriters in connection with a registered offering of $5 billion in notes by Pfizer Inc.
The notes were issued in five series with maturities ranging from 2022 to 2049, with proceeds used for general corporate purposes, including to refinance, redeem or repurchase existing debt and to repay a portion of the company’s outstanding commercial paper.
Pfizer is a research-based, global biopharmaceutical company. Pfizer’s global portfolio includes medicines, vaccines and medical devices, as well as many of the world’s best-known consumer healthcare products.
The Simpson Thacher team included Joe Kaufman, Jonathan Ozner and Davis Mahon (Capital Markets); Jon Cantor and Brian Mendick (Tax); Marcela Robledo (Intellectual Property); Jamin Koslowe (Executive Compensation and Employee Benefits); Adeeb Fadil and Noreen Lavan (Environmental); and Jennie Getsin (FINRA and Blue Sky).